Skip to search formSkip to main contentSkip to account menu

clocinnamox

Known as: 14-beta-(4-chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorpmorphine mesylate 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

CinnamatesMorphine Derivatives Including CocaineNarcotic Antagonists
methoclocinnamox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Tingenone, a Pentacyclic Triterpene, Induces Peripheral Antinociception Due to Opioidergic Activation
Abstract Plants belonging to the genus Maytenus are routinely used in folk medicine for the treatment of pain diseases. Our… 
2009
2009
Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists
In opioid pharmacology, irreversible, insurmountable antagonists have been critical experimental tools to characterize μ-opioid… 
2002
2002
CLOCINNAMOX BLOCKS ONLY MU RECEPTORS IRREVERSIBLY : BINDING
In rhesus monkey antinociception experiments, the cinnamoylaminomorphinone opioid antagonist cloeinnamox at a dose of 0.1 mg/kg… 
2000
2000
3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.
The C(3)-substituent in morphinan opioids is of critical importance; the 3-OH group is usually associated with very much higher… 
1998
1998
Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for the mu-, kappa-, or delta-receptor.
To determine the mechanism by which naltrexone (NTX) reduces oral ethanol-reinforced responding, opioid antagonists that show mu… 
1998
1998
The role of endogenous opioids in the luteinizing hormone surge in rats: studies with clocinnamox, a long-lasting opioid receptor antagonist.
1997
1997
Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
1996
1996
Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys
The antagonist effects of clocinnamox were evaluated against opioid agonists, acting at μ, κ and ∂-receptors, in rhesus monkeys… 
1996
1996
In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine
Experiments tested the hypothesis that loss of agonist potency or effectiveness following irreversible antagonist or chronic… 
1995
1995
The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)